Apalutamide

• CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids. Pending
  2025-520571-66-00 Phase III 1 country Region Vaesterbotten
• Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m… Pending
  2025-524408-30-01 Phase III 4 countries Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Gu…
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 Phase III 9 countries European Organisation For Research And Treatment Of Cancer
• FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting
  2024-517478-68-01 Phase II 1 country HUS-Yhtymae
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting
  2022-502408-57-00 Phase III 6 countries Unicancer
• Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and s… Recruiting
  2024-515049-41-00 Phase II 1 country Universita' Degli Studi Di Torino
• A Randomised study comparing Lutetium-177 versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer in PSM… Recruiting
  2022-500570-33-00 Phase III 1 country Region Västerbotten; Umea University
• Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting
  2023-506698-36-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting
  2022-502254-13-00 Phase III 1 country UZ Leuven
• "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIA… Recruiting
  2022-501894-37-00 Phase II 1 country Fondazione Radioterapia Oncologica Onlus
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 Phase III 3 countries Karolinska Institutet
• A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) w… Ended
  2024-512023-37-00 Phase II 1 country Ziekenhuis Aan De Stroom
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended
  2022-503040-41-00 Phase II 7 countries Novartis Pharma AG
• A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants with mCSPC Ended
  2022-502686-24-00 Phase III 3 countries Janssen - Cilag International
• SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended
  2023-507672-52-00 Phase I (FiH) 1 country Novartis Pharma AG
• AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy) Ended
  2024-517901-97-00 Phase II 1 country Vychodoslovensky Onkologicky Ustav a.s.
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended
  2023-508536-64-00 Phase I/II 1 country AstraZeneca AB
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended
  2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
• Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended
  2023-505852-23-00 Phase III 13 countries Janssen - Cilag International
• Study with apalutamide in patients with prostate cancer in whom the prostate has been removed who are at high risk of disease recurrence Ended
  2024-511832-29-00 Phase II 2 countries Universitaet Muenster
• A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and… Ended
  2024-514829-36-00 Phase III 1 country Unicancer
• A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended
  2023-506153-38-00 Phase III 7 countries Janssen - Cilag International
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended
  2023-505246-26-00 Phase III 9 countries Janssen - Cilag International
• A Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants with mHSPC Ended
  2023-508607-20-00 Phase III 3 countries Janssen Cilag International

Showing 1–24 of 27 trials